Roche has built the evidence for its oral BTK inhibitor fenebrutinib in multiple sclerosis (MS) with two phase 3 readouts ...
The curious finding was revealed at the American Heart Association (AHA) annual congress in New Orleans over the weekend, and ...
AstraZeneca highlighted blood pressure candidate baxdrostat as a programme to watch in its third-quarter results update, and new phase 3 data suggest that optimism is warranted. In the Bax24 study ...
The Pharmaceutical Manufacturing and Packaging Congress (PHARMAP) 2026 welcomes project leaders, procurement specialists and technical professionals from the whole value chain. On 20-21 April in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback